JP2016503394A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503394A5
JP2016503394A5 JP2015538468A JP2015538468A JP2016503394A5 JP 2016503394 A5 JP2016503394 A5 JP 2016503394A5 JP 2015538468 A JP2015538468 A JP 2015538468A JP 2015538468 A JP2015538468 A JP 2015538468A JP 2016503394 A5 JP2016503394 A5 JP 2016503394A5
Authority
JP
Japan
Prior art keywords
receptor
disease
group
conjugate according
neuropeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015538468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/072411 external-priority patent/WO2014064258A1/en
Publication of JP2016503394A publication Critical patent/JP2016503394A/ja
Publication of JP2016503394A5 publication Critical patent/JP2016503394A5/ja
Pending legal-status Critical Current

Links

JP2015538468A 2012-10-26 2013-10-25 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法 Pending JP2016503394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261719297P 2012-10-26 2012-10-26
US61/719,297 2012-10-26
EP12382413.8 2012-10-26
EP12382413 2012-10-26
PCT/EP2013/072411 WO2014064258A1 (en) 2012-10-26 2013-10-25 Compositions and methods for selective delivery of oligonucleotide molecules to cell types

Publications (2)

Publication Number Publication Date
JP2016503394A JP2016503394A (ja) 2016-02-04
JP2016503394A5 true JP2016503394A5 (https=) 2016-12-22

Family

ID=47148689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538468A Pending JP2016503394A (ja) 2012-10-26 2013-10-25 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法

Country Status (7)

Country Link
US (3) US9938525B2 (https=)
EP (1) EP2911697A1 (https=)
JP (1) JP2016503394A (https=)
AU (1) AU2013336582A1 (https=)
CA (1) CA2889608A1 (https=)
MX (1) MX2015005328A (https=)
WO (1) WO2014064258A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
RU2664452C2 (ru) 2010-04-19 2018-08-17 Нлифе Терапеутикс, С.Л. Конъюгат, медицинское средство и способы лечения и/или профилактики депрессии и болезни, связанной с отложением телец Леви
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
ES2582869T3 (es) 2011-07-05 2016-09-15 Bioasis Technologies Inc Conjugados de P97-anticuerpo
US9150858B2 (en) 2011-08-04 2015-10-06 Yeda Research And Development Co. Ltd. Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2647082T3 (es) 2012-07-31 2017-12-19 Bioasis Technologies Inc Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
AU2013336581A1 (en) 2012-10-26 2015-06-11 Nlife Therapeutics, S.L. Compositions and methods for the treatment of Parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド p97のフラグメントおよびその使用
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド P97融合タンパク質
WO2015118537A2 (en) 2014-02-05 2015-08-13 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
US10058619B2 (en) * 2014-05-01 2018-08-28 Bioasis Technologies, Inc. P97-polynucleotide conjugates
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN108135921B (zh) 2015-07-22 2023-10-17 波涛生命科学有限公司 寡核苷酸组合物及其方法
US10733023B1 (en) * 2015-08-06 2020-08-04 D2Iq, Inc. Oversubscription scheduling
GB2574525B (en) * 2015-12-21 2020-09-02 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
KR20180112060A (ko) 2016-02-23 2018-10-11 타베다 세라퓨틱스, 인코포레이티드 Hsp90 표적화된 접합체 및 이의 입자 및 제형
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
JP7206297B2 (ja) 2018-05-18 2023-01-17 エフ.ホフマン-ラ ロシュ アーゲー 大核酸の細胞内標的指向送達
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
CN109085709B (zh) * 2018-09-29 2021-07-30 昆山龙腾光电股份有限公司 一种贴附组件及贴附系统
US12478684B2 (en) 2019-04-11 2025-11-25 Northeastern University Oligonucleotide-polymer miktoarm conjugates and methods of use
EP4021574A4 (en) * 2019-08-28 2023-10-04 The Regents of the University of California BIORHYTHM MODULATORS AND THEIR USES
US20240366775A1 (en) * 2021-08-24 2024-11-07 Peptidream Inc. Human transferrin receptor binding antibody-peptide conjugate
WO2024069229A2 (en) 2022-08-03 2024-04-04 Sutura Therapeutics Ltd Biologically active compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022997A1 (en) 1995-01-27 1996-08-01 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE69637256T2 (de) 1996-01-16 2008-06-19 Sirna Therapeutics, Inc., Boulder Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
US20040087530A1 (en) 1998-02-11 2004-05-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modulating leptin activity
GB0116878D0 (en) 2001-07-11 2001-09-05 Timestrip Ltd Time indicator
US7323566B2 (en) 2004-04-23 2008-01-29 Filer Crist N Radiopharmaceutical and methods of synthesis and use thereof
US20090149512A1 (en) 2004-05-14 2009-06-11 Novo Nordisk A/S Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases
JP5266460B2 (ja) 2005-06-16 2013-08-21 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド 腎不全を治療するための方法
EP2239328A3 (en) * 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
US8193248B2 (en) 2006-03-22 2012-06-05 Starpharma Pty Limited Contraceptive composition
CN101489383A (zh) * 2006-06-01 2009-07-22 杜克大学 传递方法
US8143222B2 (en) 2007-10-22 2012-03-27 Washington University Modular platform for targeted therapeutic delivery
WO2009082607A2 (en) * 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
US20110124706A1 (en) * 2009-11-25 2011-05-26 Zhigang He SOCS3 Inhibition Promotes CNS Neuron Regeneration
RU2664452C2 (ru) 2010-04-19 2018-08-17 Нлифе Терапеутикс, С.Л. Конъюгат, медицинское средство и способы лечения и/или профилактики депрессии и болезни, связанной с отложением телец Леви
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
WO2013183656A1 (ja) * 2012-06-04 2013-12-12 大日本住友製薬株式会社 Gタンパク質共役受容体結合リガンドと核酸分子とのコンジュゲート

Similar Documents

Publication Publication Date Title
JP2016503394A5 (https=)
CN114787357A (zh) 用于编辑靶标rna的添加了功能性区域的反义型指导rna
AU2014284836B2 (en) Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease
MX2009008508A (es) Composiciones y m?todos para prevenir el c?ncer con cupredoxinas.
JP2014509511A5 (https=)
JP2014504150A5 (https=)
JP2014518612A5 (https=)
JP2010273685A5 (https=)
JP2017093448A5 (https=)
JP2015522264A5 (https=)
JP2018512876A5 (https=)
TR201815415T4 (tr) Fibroz tedavisi.
JP2010540453A5 (https=)
US9586944B2 (en) Specific targeting of RNA expanded repeat sequences
WO2007056153B1 (en) Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
Vo et al. Building of neomycin–nucleobase–amino acid conjugates for the inhibition of oncogenic miRNAs biogenesis
JP2018533956A5 (https=)
WO2019196887A1 (zh) 一种新型小激活rna
IL273578B1 (en) Antibodies targeting pdl1 and methods of use thereof
CN105722979A (zh) 肝癌相关的基因特异性siRNA、包含所述siRNA的双链寡RNA分子和包含它们的用于预防或治疗癌症的组合物
JP2013537404A5 (https=)
NZ604094A (en) Double stranded rna compounds to rhoa and use thereof
JP2017000155A (ja) 線維症予防又は治療剤
EP3710015B1 (en) Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
Ren et al. Chromatin-associated α-satellite RNA maintains chromosome stability by reestablishing SAF-A in the mitotic cell cycle